CellaVision AB (publ) CEVI.ST Open CellaVision AB (publ) in new tab
CellaVision AB (publ) Analysis (CEVI.ST)
Is CellaVision AB (publ) a good investment? CellaVision AB (publ) (CEVI.ST) is currently trading at 122.80 SEK. Market analysts have a consensus price target of 179.00 SEK. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 21.92. This valuation is generally in line with the broader market.
Earnings Schedule: CellaVision AB (publ) is expected to release its next earnings report on July 16, 2026. The market consensus estimate for Forward EPS is 8.22.
For income investors, CellaVision AB (publ) pays a dividend yield of 2.24%. With a payout ratio of 44%, the dividend appears sustainable.
Investor FAQ
Does CellaVision AB (publ) pay a dividend?
Yes, it pays an annual dividend of 2.75 SEK (2.24% yield).
What asset class is CellaVision AB (publ)?
CellaVision AB (publ) is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 16, 2026. The company currently has a trailing EPS of 5.62.
Company Profile
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Dividend Yield
2.24% (5y avg: 0.92%)
Annual Dividends
2.75 SEK
Next ex. div date
April 29, 2026
Payout Ratio
44.48%
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2026 | 2.75 SEK |
| May 6, 2026 | 2.7500 |
| 2025 | 2.50 SEK |
| May 13, 2025 | 2.5000 |
| 2024 | 2.25 SEK |
| May 13, 2024 | 2.2500 |
| 2023 | 2.25 SEK |
| May 12, 2023 | 2.2500 |
| 2022 | 2.00 SEK |
| May 18, 2022 | 2.0000 |
| 2021 | 0.75 SEK |
| May 6, 2021 | 0.7500 |
| 2019 | 1.50 SEK |
| May 15, 2019 | 1.5000 |
| 2018 | 1.50 SEK |
| May 14, 2018 | 1.5000 |
| 2017 | 1.50 SEK |
| May 12, 2017 | 1.5000 |
| 2016 | 1.50 SEK |
| May 6, 2016 | 1.5000 |
| 2015 | 1.00 SEK |
| May 7, 2015 | 1.0000 |
| 2014 | 0.50 SEK |
| May 8, 2014 | 0.5000 |
| 2013 | 0.40 SEK |
| April 25, 2013 | 0.4000 |
| 2012 | 0.40 SEK |
| May 3, 2012 | 0.4000 |
Yearly aggregated dividends
Dividends
|
CellaVision AB (publ)
May 06, 2026 Paid
Dividend
2.75 SEK |
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion